[go: up one dir, main page]

SG11202001728YA - Enpp1 inhibitors and their use for the treatment of cancer - Google Patents

Enpp1 inhibitors and their use for the treatment of cancer

Info

Publication number
SG11202001728YA
SG11202001728YA SG11202001728YA SG11202001728YA SG11202001728YA SG 11202001728Y A SG11202001728Y A SG 11202001728YA SG 11202001728Y A SG11202001728Y A SG 11202001728YA SG 11202001728Y A SG11202001728Y A SG 11202001728YA SG 11202001728Y A SG11202001728Y A SG 11202001728YA
Authority
SG
Singapore
Prior art keywords
cancer
treatment
enpp1 inhibitors
enpp1
inhibitors
Prior art date
Application number
SG11202001728YA
Other languages
English (en)
Inventor
Lingyin Li
Mark Smith
Kelsey Erin Shaw
Jacqueline Ann Carozza
Volker Boehnert
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of SG11202001728YA publication Critical patent/SG11202001728YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/091Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/16Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165Esters of thiophosphoric acids
    • C07F9/1651Esters of thiophosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3826Acyclic unsaturated acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44Amides thereof
    • C07F9/4403Amides thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4407Amides of acyclic saturated acids which can have further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202001728YA 2017-09-08 2018-09-07 Enpp1 inhibitors and their use for the treatment of cancer SG11202001728YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762556117P 2017-09-08 2017-09-08
PCT/US2018/050018 WO2019051269A1 (en) 2017-09-08 2018-09-07 ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
SG11202001728YA true SG11202001728YA (en) 2020-03-30

Family

ID=63714052

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001728YA SG11202001728YA (en) 2017-09-08 2018-09-07 Enpp1 inhibitors and their use for the treatment of cancer

Country Status (18)

Country Link
US (3) US11701371B2 (da)
EP (2) EP3678668B1 (da)
JP (2) JP7292740B2 (da)
KR (2) KR20240151869A (da)
CN (2) CN117883449A (da)
AU (2) AU2018330188C1 (da)
BR (1) BR112020004559A2 (da)
CA (1) CA3074268A1 (da)
DK (1) DK3678668T3 (da)
EA (1) EA202090595A1 (da)
ES (1) ES2975183T3 (da)
HU (1) HUE066413T2 (da)
IL (3) IL302338B2 (da)
MA (1) MA50082A (da)
MX (2) MX2020002646A (da)
PL (1) PL3678668T3 (da)
SG (1) SG11202001728YA (da)
WO (1) WO2019051269A1 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3902787A4 (en) * 2018-12-28 2022-12-28 Riboscience LLC Quinazoline derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
HRP20231413T1 (hr) 2019-04-12 2024-02-16 Riboscience Llc Derivati bicikličnih heteroarila kao inhibitori ektonukleotid pirofosfataze fosfodiesteraze 1
MX2022003183A (es) 2019-09-16 2022-06-08 Aten Porus Lifesciences Pvt Ltd Compuestos de tiopurina 2-amino-s6-sustituidos como inhibidores de la proteína ectonucleótido pirofosfatasa/fosfodiesterasa 1 (enpp1).
JP7654643B2 (ja) * 2019-09-23 2025-04-01 ナンジン ゼンシャイン ファーマシューティカルズ カンパニー リミテッド ホスホジエステラーゼ阻害剤および使用
JP2023514550A (ja) * 2020-02-04 2023-04-06 スティングレイ・セラピューティクス・インコーポレイテッド エクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ1(enpp1)の阻害剤およびその使用方法
KR20220143064A (ko) 2020-02-18 2022-10-24 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
CN115362150A (zh) * 2020-04-09 2022-11-18 贝达药业股份有限公司 Enpp1抑制剂及其组合物和用途
WO2021225969A1 (en) * 2020-05-04 2021-11-11 Volastra Therapeutics, Inc. Imino sulfanone inhibitors of enpp1
KR102682428B1 (ko) 2020-05-08 2024-07-05 주식회사 티씨노바이오사이언스 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 프탈라진 유도체 및 이들의 용도
CN115515939B (zh) 2020-05-08 2024-12-13 谛希诺生物科技有限公司 具有抑制外核苷酸焦磷酸酶-磷酸二酯酶的活性的新型酞嗪衍生物及它们的用途
US12091412B2 (en) 2020-06-16 2024-09-17 Volastra Therapeutics, Inc. Heterocyclic inhibitors of ENPP1
TW202227407A (zh) * 2020-09-03 2022-07-16 美商免疫感應治療公司 喹啉cGAS拮抗劑化合物
WO2022091048A1 (en) 2020-10-30 2022-05-05 Integral Biosciences Private Limited Ectonucleotide pyrophosphatase-phosphodiesterase-1 (enpp1) inhibitors and uses thereof
CN116600813A (zh) * 2020-12-09 2023-08-15 斯汀格瑞治疗股份有限公司 作为enpp1和cdnp抑制剂的膦酸盐
JP2024500249A (ja) * 2020-12-09 2024-01-05 スティングレイ・セラピューティクス・インコーポレイテッド Enpp1およびcdnpの阻害剤としてのホスホネート類
MX2023007670A (es) * 2020-12-29 2023-07-07 Txinno Bioscience Inc Nuevo derivado de naftiridinona que tiene actividad inhibidora contra la ectonucleotido pirofosfatasa -fosfodiesterasa y uso del mismo.
KR102720206B1 (ko) 2020-12-29 2024-10-21 주식회사 티씨노바이오사이언스 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 나프티리딘온 유도체 및 이들의 용도
KR102686866B1 (ko) 2021-01-29 2024-07-19 주식회사 티씨노바이오사이언스 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 벤조트리아졸 유도체 및 이들의 용도
WO2022164249A1 (ko) 2021-01-29 2022-08-04 주식회사 티씨노바이오사이언스 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 벤조트리아졸 유도체 및 이들의 용도
WO2022197734A1 (en) * 2021-03-16 2022-09-22 Riboscience Llc Bicyclic heteroaryl boronate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
CN117120444A (zh) 2021-04-16 2023-11-24 吉利德科学公司 使用酰胺制备卡巴核苷的方法
CN115536696B (zh) * 2021-06-29 2023-07-14 上海齐鲁制药研究中心有限公司 Enpp1抑制剂
WO2023023527A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
WO2023035001A1 (en) * 2021-09-03 2023-03-09 Angarus Therapeutics, Inc. Enpp1 inhibitors and immune cells expressing chimeric antigen receptors
WO2023077083A1 (en) * 2021-10-29 2023-05-04 Angarus Therapeutics, Inc. Enpp1 inhibitors as inhibitors of metastasis
IL315346A (en) 2022-03-02 2024-11-01 Immunesensor Therapeutics Inc CGAS agonistic quinoline compounds
US20250206763A1 (en) * 2022-04-11 2025-06-26 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Enpp1 inhibitor
CN114767863B (zh) * 2022-04-29 2024-01-30 西北工业大学 一种enpp2基因或蛋白在调控结直肠癌细胞中的应用
WO2023212154A1 (en) 2022-04-29 2023-11-02 Petragen, Inc. Inhibitors of enpp1 and modulation of bone growth
EP4565586A1 (en) * 2022-08-01 2025-06-11 Sravathi Ai Technology Private Limited Novel ectonucleotide pyrophosphatase / phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
WO2024213932A1 (en) * 2023-04-11 2024-10-17 The Hong Kong University Of Science And Technology Driving axon regeneration by novel enpp1 inhibitors
WO2024216211A2 (en) * 2023-04-14 2024-10-17 The Board Of Trustees Of The Leland Stanford Junior University Methods of inhibiting tumor progression and metastasis by inhibition of enpp1

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA228044A (en) 1923-01-16 Thomas Noble Boughton Die for forming bolts
CA190896A (en) 1919-02-24 1919-06-17 Josephat C. Bergeron Advertising device
DE3319795A1 (de) 1983-06-01 1984-12-06 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von phosphonsaeureestern
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
CN1113066C (zh) 1995-04-21 2003-07-02 帝国脏器制药株式会社 新型肽衍生物
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
WO2002072578A2 (en) * 2001-03-08 2002-09-19 Millennium Pharmaceuticals (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP1578755B1 (en) 2002-12-24 2007-08-22 AstraZeneca AB Phosphonooxy quinazoline derivatives and their pharmaceutical use
US20070004763A1 (en) 2005-06-10 2007-01-04 Nand Baindur Aminoquinoline and aminoquinazoline kinase modulators
US10543207B2 (en) 2008-12-31 2020-01-28 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP2621923B1 (en) * 2010-09-29 2017-03-29 Intervet International B.V. N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases
WO2013096680A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
EP2992000B1 (en) 2013-05-03 2020-07-08 The Regents of The University of California Cyclic di-nucleotide induction of type i interferon
SMT201900635T1 (it) 2013-05-18 2020-01-14 Univ California Composizioni e metodi di attivazione della segnalazione dipendente dallo "stimolatore di geni interferone"
WO2016048861A2 (en) * 2014-09-22 2016-03-31 National Health Research Institutes Heterocyclic compounds and use thereof
WO2016049568A1 (en) * 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
CN105153153A (zh) 2015-08-31 2015-12-16 吉林奥来德光电材料股份有限公司 一种新的芳香族胺类化合物及其制备与应用
TWI659949B (zh) 2016-05-16 2019-05-21 臺北醫學大學 組蛋白去乙醯酶6抑制劑及其用途
CN110461334A (zh) 2016-12-22 2019-11-15 马福制药公司 增强或增加i型ifn产生的组合物和方法
CN110312424A (zh) 2017-01-09 2019-10-08 澳大利亚国立大学 用于改善杀虫剂的增效剂
US10518257B2 (en) 2017-05-04 2019-12-31 Exxonmobil Research And Engineering Company Metal organic frameworks, their synthesis and use
WO2018229139A1 (en) 2017-06-14 2018-12-20 Fundación Para La Investigación Médica Aplicada Novel compounds for use in cancer
TW201920104A (zh) 2017-08-31 2019-06-01 美商馬愈法瑪公司 外核苷酸焦磷酸酶-磷酸二酯酶1(enpp-1)抑制劑及其用途
US20220289775A1 (en) 2019-02-01 2022-09-15 The Board Of Trustees Of The Leland Stanford Junior University ENPP1 Inhibitors and Methods of Modulating Immune Response
CN114437128B (zh) * 2022-01-28 2023-12-19 中国科学院长春应用化学研究所 一种胆碱磷酸修饰的紫杉醇药物及其制备方法和应用

Also Published As

Publication number Publication date
US20230103498A1 (en) 2023-04-06
KR20240151869A (ko) 2024-10-18
KR102715420B1 (ko) 2024-10-10
HUE066413T2 (hu) 2024-08-28
JP2023101715A (ja) 2023-07-21
EP3678668A1 (en) 2020-07-15
RU2020112299A3 (da) 2022-03-14
US20230277570A1 (en) 2023-09-07
EA202090595A1 (ru) 2020-06-29
US11707471B2 (en) 2023-07-25
JP7607969B2 (ja) 2025-01-06
PL3678668T3 (pl) 2024-06-03
MX2023007193A (es) 2023-07-03
MX2020002646A (es) 2020-09-25
EP3678668B1 (en) 2024-01-10
IL272948B2 (en) 2023-09-01
AU2018330188A1 (en) 2020-04-23
ES2975183T3 (es) 2024-07-03
IL311010A (en) 2024-04-01
EP4327882A2 (en) 2024-02-28
EP4327882A3 (en) 2024-05-15
RU2020112299A (ru) 2021-10-08
MA50082A (fr) 2020-07-15
AU2018330188B2 (en) 2023-10-19
IL272948A (en) 2020-04-30
IL302338B2 (en) 2024-10-01
AU2018330188C1 (en) 2024-02-29
BR112020004559A2 (pt) 2020-09-24
CN117883449A (zh) 2024-04-16
CN111372587A (zh) 2020-07-03
JP7292740B2 (ja) 2023-06-19
AU2024200148A1 (en) 2024-01-25
IL272948B1 (en) 2023-05-01
IL302338B1 (en) 2024-06-01
KR20200066292A (ko) 2020-06-09
DK3678668T3 (da) 2024-04-08
CA3074268A1 (en) 2019-03-14
IL302338A (en) 2023-06-01
JP2020533288A (ja) 2020-11-19
US20210369747A1 (en) 2021-12-02
US11701371B2 (en) 2023-07-18
WO2019051269A1 (en) 2019-03-14
CN111372587B (zh) 2024-01-09

Similar Documents

Publication Publication Date Title
IL272948B1 (en) enpp1 inhibitors and their use for cancer treatment
IL256874B (en) Immune checkpoint suppressors for use in the treatment of blood-borne cancers
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
IL270511A (en) Combination therapies using niraparib and pembrolizumab for treating cancer
IL258741B (en) Combination of bcl-2 inhibitor and mek inhibitor for cancer treatment
IL267795A (en) Combined treatment for cancer
ZA201900960B (en) Methods and compositions for the treatment of cancer
IL248455A0 (en) igf-1r antibody-drug conjugate and its use for cancer treatment
IL254103A0 (en) Compositions and methods for increasing the effectiveness of cancer treatment
IL264451B1 (en) A combination of abt-199 and achmetalstat for the treatment of aml
IL247586A0 (en) Use of Aribolin and mtor inhibitors as a combined treatment for cancer
HUE053927T2 (hu) Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra
IL274198A (en) Use of Nox inhibitors to treat cancer
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
IL280587B (en) Fluorocitidine derivatives and their preparations for use in cancer treatment
IL266993A (en) Combined therapy for cancer treatment
ZA201900984B (en) Methods and compositions for the treatment of warts
IL269121A (en) Usl-311 for use in the treatment of cancer
SG11202000724XA (en) Methods and compositions for the treatment of cancer
IL253642A0 (en) Combined treatment for cancer
HK40018432A (en) Usl-311 for use in the treatment of cancer